

## Media release

### **Straumann shareholders approve all proposals at AGM**

- *20% increase in dividend approved*
- *Dominik Ellenrieder and Dr h.c. Thomas Straumann re-elected*

**Basel, 30 March 2007:** At their Annual General Meeting in Basel, the shareholders of Straumann Holding AG voted in favor of all the proposals of the Board of Directors. 770 shareholders were present, representing 61% of the company's 15.6 million shares.

#### **Appropriation of available earnings**

The meeting voted on the appropriation of the available earnings, which totalled CHF 335 million. Of this, CHF 46.8 million were approved for the 2006 dividend, corresponding to an increase of 20% over the previous year and a dividend payout ratio of 33% of net profit. The dividend, which amounts to CHF 3.00 per share, will be paid as of 4 April 2007.

#### **Re-elections to the Board**

Mr Dominik Ellenrieder and Dr h.c. Thomas Straumann were both re-elected to the Board of Directors for a further period of three years.

Apart from this, the meeting approved: the 2006 Annual Report and Financial Statements, the discharge of the Board of Directors for their activities in 2006, and the reappointment of PricewaterhouseCoopers, Basel, as Statutory Auditors and Group Auditors for a term of one year.

#### **Foundation for superior growth**

In his address, the Chairman of the Board, Dr h.c. Rudolf Maag, reviewed Straumann's progress over the past year and shared his view of things to come. He noted that the Group had achieved much in 2006 and had laid the foundations for superior future growth. The achievements he highlighted included the introduction of key innovative products, the expansion of infrastructure and the improvement of organizational structures and processes. He also discussed the recent acquisition of etkon, which positions Straumann uniquely as the only company offering a complete range of surgical, restorative and regenerative solutions to dental professionals and patients. Dr Maag reiterated the Group's optimism about the growth opportunities in the field of implant dentistry and dental tissue regeneration. He concluded that - by virtue of its innovation and service leadership - Straumann is confident of its ability to grow above market in the years ahead, while further expanding margins, thanks to improving operational excellence.

#### **AGM in 2008**

The Chairman announced that the next ordinary general meeting of the shareholders will be held on 27 March 2008 at the same location (Basel Trade-Fair Congress Center).

**Straumann Holding AG**, Peter Merian-Weg 12, 4002 Basel, Switzerland.  
Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01  
E-mail: [investor.relations@straumann.com](mailto:investor.relations@straumann.com) or [corporate.communication@straumann.com](mailto:corporate.communication@straumann.com)  
Homepage: [www.straumann.com](http://www.straumann.com)

**Contact:**

Mark Hill, Corporate Communication: +41 (0)61 965 1321

**Concerning forward looking statements**

This release contains certain “forward-looking statements”, which can be identified by the use of terminology such as “will”, “further”, “future”, “optimism”, “growth opportunities”, “confident”, “ability to grow”, “ahead”, “improving”, or similar wording. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group’s products, the potential for the Group’s products to become obsolete, the Group’s ability to defend its intellectual property, the Group’s ability to develop and commercialize new products in a timely manner, the dynamic and competitive environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group’s ability to generate revenues and profitability, and the Group’s ability to realize its expansion projects in a timely manner. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.

**About Straumann**

Headquartered in Basel, Switzerland, the Straumann Group (SWX: STMN) is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, the Group researches and develops implants, instruments and tissue regeneration products for use in tooth replacement solutions or to prevent tooth loss. The Group manufactures implant system components and instruments in Switzerland and the US and dental tissue regeneration products in Sweden. Straumann also offers comprehensive training and services to the dental profession worldwide, including training and education, which is provided in collaboration with the International Team for Implantology (ITI). Recently, Straumann entered the fast-growing field of restorative dentistry through the acquisition of etkon, an emerging force in CAD/CAM based tooth replacement. Including etkon, Straumann employs approximately 1630 people worldwide and its products and services are available in more than 60 countries through its own distribution subsidiaries and broad network of distribution partners.

**Key reporting dates in 2007**

3 May	Q1 sales
9 August	Q2 sales and H1 results
2 November	Q3 and 9M sales

Details and further information are available on [www.straumann.com](http://www.straumann.com).